Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
站內檢索
:::
▍研究室
:::

醣生物學研究室

TEL: +886-2-28712121 Ext.27778
E-mail: [email protected]
 主持人：梁毓津
2002 ~2008  國防醫學大學生命科學所博士
2008 ~ 2011中央研究院基因體中心幹細胞中心博士後研究員
2011 ~ 2013美國華盛頓大學博士後研究員
2013 ~ 2017長庚紀念醫院醫學研究部助理研究員
2017 ~迄今 長庚科技大學兼任助理教授
2017 ~2021臺北榮民總醫院醫學研究部高級助理研究員
2021~迄今 臺北榮民總醫院醫學研究部 副研究員
2021~迄今 國立陽明交通大學臨床醫學研究所兼任助理教授		 梁毓津博士
《研究興趣》
(1) 癌症糖鞘脂與腫瘤微環境的關係
(2) 醣鞘脂及醣蛋白在癌症診斷及治療上的應用
(3) 以肝癌特異性表達之醣鞘脂開發肝癌生物標誌並研究其應用於癌症診斷或免疫
(4) 肝炎病毒與肝癌研究
《近期研究著作》

1. Liang YJ, Chiou YW, Chiu AP, Shiao MS, Teng W, Lin CW, Cheng ML, et al. Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR-122. J Med Virol 2023;95:e29325. (FIRST-AUTHOR, IF 20.693, Rank: 2/36, JIF 95.8%, VIROLOGY)

2. Wang SY, Huang YH, Liang YJ, Wu JC. Gene coexpression network analysis identifies hubs in hepatitis B virus-associated hepatocellular carcinoma. J Chin Med Assoc 2022;85:972-980. (CO-AUTHOR, IF 3.396, Rank:78/329, JIF 59.01%, MEDICINE, GENERAL & INTERNAL)

3. Chang YS, Su CW, Chen SC, Chen YY, Liang YJ, Wu JC. Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. Cells 2022;11. (IF 7.666, Rank:51/194, 73.97%, CELL BIOLOGY)

4. Liang YJ. Glycosphingolipids in human embryonic stem cells and breast cancer stem cells, and potential cancer therapy strategies based on their structures and functions. Glycoconj J 2022;39:177-195. (Invited review article; FIRST AUTHOR and CORRESPONDING AUTHOR, IF 3.456, Rank: 143/299, 52.34%. BIOCHEMISTRY & MOLECULAR BIOLOGY)

5. Liang YJ, Teng W, Chen CL, Sun CP, Teng RD, Huang YH, Liang KH, et al. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development. Hepatology 2021;74:641-655. (FIRST AUTHOR, IF17.425, Rank: 6/131, 95.80%, GASTROENTEROLOGY AND HEPATOLOGY)

6. Liang YJ, Sun CP, Hsu YC, Chen YW, Wang IA, Su CW, Tao MH, et al. Statin inhibits large hepatitis delta antigen-Smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion. J Biomed Sci 2020;27:65. (FIRST AUTHOR, IF 12.771, Rank: 11/139, 92.45%, MEDICINE, RESEARCH & EXPERIMENTAL)

7. Wang SY, Chen CL, Hu YC, Chi Y, Huang YH, Su CW, Jeng WJ, et al. High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. Cancers (Basel) 2019;11. (CO-AUTHOR, IF 6.639, Rank 31/280, 85.04%, ONCOLOGY)

8. Cheng KC, Lin RJ, Cheng JY, Wang SH, Yu JC, Wu JC, Liang YJ, et al. FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding. EBioMedicine 2019;45:25-38. (CO-AUTHOR, IF 11.205, Rank 11/195, 94.62%, MEDICINE, RESEARCH & EXPERIMENTAL)

9. Chen CL, Tsai YS, Huang YH, Liang YJ, Sun YY, Su CW, Chau GY, et al. Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelial-Mesenchymal Transition Regulators and Stemness Genes. Hepatol Commun 2018;2:1392-1407. (CO-AUTHOR, IF 5.701, Rank 30/135, 78.15%, GASTROENTEROLOGY & HEPATOLOGY)

10. Liang YJ, Wang CY, Wang IA, Chen YW, Li LT, Lin CY, Ho MY, et al. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget 2017;8:47454-47473. (FIRST AUTHOR and CORRESPONDING AUTHOR, IF 5.168, Rank: 44/217 Q1, 79.954%, ONCOLOGY)

11. Liang YJ, Ding Y, Levery SB, Lobaton M, Handa K, Hakomori SI. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A 2013;110:4968-4973. (FIRST AUTHOR, IF 9.809; Rank 4/55; JIF Percentile 93.636%, MULTIDISCIPLINARY SCIENCES)

12. Liang YJ, Yang BC, Chen JM, Lin YH, Huang CL, Cheng YY, Hsu CY, et al. Changes in glycosphingolipid composition during differentiation of human embryonic stem cells to ectodermal or endodermal lineages. Stem Cells 2011;29:1995-2004. (FIRST AUTHOR, IF 7.781; Rank 7/158; JIF Percentile 95.886%, BIOTECHMOLOGY & APPLIED MICROBIOLOGY)

13. Liang YJ, Kuo HH, Lin CH, Chen YY, Yang BC, Cheng YY, Yu AL, et al. Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation. Proc Natl Acad Sci U S A 2010;107:22564-22569. (FIRST AUTHOR, IF 9.771; Rank 3/59; JIF Percentile 95.763%, MULTIDISCIPLINARY SCIENCES)

14. Chang HS, Lin CH, Yang CH, Liang YJ, Yu WC. The human papillomavirus-16 (HPV-16) oncoprotein E7 conjugates with and mediates the role of the transforming growth factor-beta inducible early gene 1 (TIEG1) in apoptosis. Int J Biochem Cell Biol 2010;42:1831-1839. (JOINT AUTHOR, IF=4.956; R/C= 58/286; JIF Percentile= 79.895%, BIOCHEMISTRY & MOLECULAR BIOLOGY)

15. Liang YJ, Chang HS, Wang CY, Yu WC. DYRK1A stabilizes HPV16E7 oncoprotein through phosphorylation of the threonine 5 and threonine 7 residues. Int J Biochem Cell Biol 2008;40:2431-2441. (FIRST AUTHOR, IF=4.887; R/C= 56/283, JIF Percentile= 80.389%, BIOCHEMISTRY & MOLECULAR BIOLOGY)

16. Chang HS, Lin CH, Yang CH, Yen MS, Lai CR, Chen YR, Liang YJ, et al. Increased expression of Dyrk1a in HPV16 immortalized keratinocytes enable evasion of apoptosis. Int J Cancer 2007;120:2377-2385. (JOINT AUTHOR, IF=5.720; R/C= 31/211, JIF Percentile= 85.545%, ONCOLOGY)

17. Wang CY, Liang YJ, Lin YS, Shih HM, Jou YS, Yu WC. YY1AP, a novel co-activator of YY1. J Biol Chem 2004;279:17750-17755. (co-FIRST AUTHOR, IF=6.355; R/C= 31/261, JIF Percentile= 88.314%, BIOCHEMISTRY & MOLECULAR BIOLOGY)

 

《BOOKS》

1. Yuh-Jin Liang, Kay-Hooi Khoo, and John Yu. Roles of Glycosphingolipid Structures in Human Embryonic Stem Cells and Breast Cancer Stem Cells. The Molecular Immunology of Complex of Carbohydrates-4 (MMIC4): Cancer and Stem Cell Biology. Editor Albert M. M. Wu , Springer -Verlag London Ltd, UK.

2.梁毓津、洪榮堂、陳鈴津、游正博。 醣鞘脂於胚胎幹細胞分化過程之變化與癌免疫治療之應用. (Book Chapter) 2018年09月; 再生醫學：臨床與產業應用（ISBN：978-986-05-6694-9,p 59-83）。台灣,中華民國：科技部再生醫學科技發展計畫辦公室出版。
《受邀演講》
  1. Liang, YJ, Yu, J, Hakomori SI: “Selection of Stem Cells Specific Markers by Glycosphingolipidomics for Potential Use in Cancer Diagnosis and Therapy”, Oral presented at 2013 International Glycoforum in Wuxi, Jiangnan University, China. September 16-17, 2013.
  2. Yuh-Jin Liang, Jaw-Ching Wu*: “以細胞培養與人肝嵌合小鼠模式探討B型肝炎病毒野生型與刪除型突變株的外套抗原前區影響病毒複製、裝配、釋放與致病性的關鍵區域與氨基酸”, Oral presented at 2018 Annual VTA Joint Project Symposium, Academia Sinica, Taipei, Nov 26, 2018.
  3. Yuh-Jin Liang, Jaw-Ching Wu*: “The pre-S2 deletion HBV mutants are responsible for the intracellular accumulation of the HBs protein, ER stress and mitochondria dysfunction”, Oral presented at 2019 Annual VTA Joint Project Symposium, Academia Sinica, Taipei, Jun 22, 2019.
  4. Yuh-Jin Liang, Jaw-Ching Wu*: “研究肝癌伴隨的醣鞘脂及其代謝的特異性表達以發展肝癌診斷與治療策”, invited oral presented at 高雄榮民總醫院教學研究部, Dec, 27, 2019.
  5. Yuh-Jin Liang, Rui-Dung Teng, Cheng-Pu Sun, Chien-Wei Su, Yi Chi, Ming-Hua Tao, Jaw-Ching Wu*: “The pre-S2 deletion HBV mutants are responsible for the intracellular accumulation of the HBs proteins, ER stress and mitochondria dysfunction”, Oral presented at The International Liver Congress™ 2019, Vienna, Austria, April 10-14, 2019.
  6. Yuh-Jin Liang, Teng W, Chen CL, Sun CP, Teng RD, Huang YH, Liang KH, Chen YW, Lin CC, Su CW, Tao MH, Wu JC. Clinical implications on HBV preS/S mutations and the effects of preS2 deletion on mitochondria, liver fibrosis, and cancer development. Oral presented at the 17th ISVHLD GHS 2020/2021, Taipei, Taiwan, Jun 18-20, 2021.
  7. Yuh-Jin Liang, Mechanisms of hijack of autophagy by HBV and mitochondrial dysfunction in liver injury. Lecture presented at 2023 TASL Single Topic Conference (STC), July 1st, 2023.Tainan, Taiwan.
  8. Yuh-Jin Liang, Autophagy and hepatitis B virus replication, pathogenesis, and clinical treatment implications. Oral presented at陽明交通大學校級演講Jun 30, 2023, Taipei, Taiwan.
  9. The Impact of HBV PreS2 Deletion Mutation and Single-Nucleotide Variants on Hepatocellular Carcinoma Development and the Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients. Invited speak at Mongolian Digestive Disease Week 2024. Jun 19, 2024, Ulaanbaatar, Mongolia.
  10. 114年度臺北榮民總醫院x國立陽明交通大學雙邊合作會議,自噬機制以及粒線體功能異常與人類疾病的關係專題, Invited speaker and Modulator, Jan 3, 2025, Taipei, Taiwan.
《獎項》
  1. Ph.D. Student Thesis Research Award, 2008 June
    國防醫學院 博士班畢業論文獎
  2. Academia Sinica Postdoctoral Research Fellowships, 2009 July- 2011 Jun.
    中研院博士後研究員全額獎助金
  3. Award of the Society for Glycobiology and the American Society for Matrix Biology, 2012 November.
    美國醣生物學會年會研究成果獎
  4. Research Incentive Award of Chang-Gung medical foundation, 2013- 2016.
    林口長庚醫院研究獎勵金 2013-2016
  5. Annual Performance Evaluations for Principle Investigators of CGMH: Ranked First in 4 category (the achievement of funding, publication, teaching, science community service and editorial/ review activities) as excellent performance PI in 2017.
    林口長庚醫院年度評鑑為最高級優秀研究人員
  6. The Best Research Report Award of 2019. Taipei Veterans General Hospital.
    臺北榮民總醫院108年度 (2019) 院內計畫成果報告獲評優等
  7. Research paper award 2020, Taipei Veterans General Hospital.
    臺北榮民總醫院109年度 (2020) 研究論文獎勵金得主.
  8. Journal paper award in First season of 2021, National Yang Ming Chiao Tung University,
    陽明交通大學110年(2021)第一季重要期刊論文獎
  9. Scientific Paper Award –Research Fellow group 2021.
    臺北榮民總醫院110年度(2021)「學術論文獎-研究人員組」第三名
  10. Research paper award 2021, Taipei Veterans General Hospital.
    臺北榮民總醫院110 (2021)年度研究論文獎勵金得主
  11. Poster Award of Annual Meeting of TVGH – AS Joint Program
    第十八屆(2022年)榮台聯大合作研究成果壁報獎
  12. Scientific Paper Award –Research Fellow group 2022.
    臺北榮民總醫院111年度(2022)「學術論文獎-研究人員組」第二名
  13. Scientific Paper Award –Research Fellow group 2024.
    臺北榮民總醫院113年度(2024)「學術論文獎-研究人員組」第一名
《執行中計畫》

Active Grants

Principal Investigator計畫主持人

1. National Science and Technology Council Grant
國科會個別型專題計畫NSTC 113-2314-B-075 -052 -MY3
2024/08/01-- 2027/07/31, Principal Investigator, “Exploring Sphingolipid Signaling mediated by Lysosomal Sphingolipid Activator Proteins on Regulating HBV Replication and Secretory Pathway for Potential Intervention Strategy in HBV- associated HCC”. Annual Direct Costs: NTD 1,350,000; Total Direct Costs: NTD 4,050,000

2. Taipei Veterans General Hospital Research Gran,
榮總院內C計畫, 2025/01/01-- 2027/12/31, V114C-, V115C-; V116C-. Principal Investigator, “Investigating the Impact of HBV and Lysosomal Sphingolipid Activating Proteins Interaction on Lysosomal Function and Its Potential in HBV-associated HCC Treatment”, Annual Direct Costs: NTD 880,000; Total Direct Costs: NTD 2,640,000

3. Taipei Veterans General Hospital – Academia Sinica Joint Program,
VTA114-V1-7-2, 榮總-中研院合作計畫2025/01/01 --2027/12/31, “Using HBV-associated hepatocellular carcinoma mouse models to explore the changes in Key Spatial Features of the Tumor Microenvironment under antiviral therapy”, Annual Direct Costs: NTD 883,000


Co-Principal Investigator共同/協同主持人

1. National Cancer Control Program /Phase IV, supported by Ministry of Health and Welfare of Taiwa. MOHW111-TDU-B-221-014007. 衛福部癌症卓越計畫
20220101—20251231, Theme1-1 The impact and prediction value of single-nucleotide variants, Pre-S/S mutants and splicing mutants in hepatitis B virus-related hepatocellular carcinoma. Principal Investigator吳俊穎副院長

2. Higher Education Sprout Project, supported by Ministry of Education of Taiwan 111W31101- 111W31205.高教深耕2.0計畫
20220101-20251231 Exploration and clinical application of tumor microenvironment. Principal Investigator楊慕華副校長

3. National Science Council Grant, MOST 111-2923-B-A49-001 國科會臺蒙雙邊協議型國際合作研究計畫
20220101-20250331 Development of a Novel LAMP PCR Diagnostic Method for Epidemiology and Prevention of Hepatitis D Virus Infection in Mongolia. Principal Investigator吳肇卿講座教授

4. National Science Council Gran, MOST 111-2314-B-A49-047 國科會個別型專題計畫
20220801-20250731 The role of HBV replication on lipid dysregulation, mitochondrial dysfunction and HCC. Principal Investigator吳肇卿講座教授.

5. National Science and Technology Council Gran, NSTC 113-2314-B-A49-043 國科會個別型專題計畫
20240801-20270731 Investigate the role and mechanisms of microRNA on USP22 and ABCC1 in multiple kinase inhibitor-resistant hepatocellular carcinoma, for innovative and combination treatments. Principal Investigator吳肇卿講座教授

最後更新：

回到最上